Tag: Cftr modulators

According to market analysis following its late 2024 approval, Alyftrek carries an annual list price of approximately $370,000, representing a premium of about 7% over the established CF treatment, Trikafta. Understanding **how much does Alyftrek cost compared to Trikafta?** is critical for patients, providers, and healthcare systems navigating treatment options for cystic fibrosis (CF), as the comparison involves more than just the sticker price.

Traditionally, cystic fibrosis (CF) has been managed with treatments that address symptoms rather than the underlying cause. The emergence of Trikafta has revolutionized this approach, providing a targeted therapy that directly addresses the defective protein, significantly improving lung function and overall health for many with CF.

In clinical trials, a significant number of patients on Trikafta reported experiencing side effects, with some of the most common including headaches and upper respiratory tract infections. Understanding **what are the side effects of Trikafta** is crucial for patients and healthcare providers to manage expectations and ensure safety during treatment.

Breakthroughs in targeted therapy have transformed the treatment landscape for cystic fibrosis, with approximately 90% of eligible patients now benefiting from highly effective modulators. Today, the answer to what is the drug of choice for cystic fibrosis depends on a patient's specific genetic mutation, shifting the focus from symptom management to correcting the underlying cause.

The life expectancy for people with cystic fibrosis has dramatically improved over the past few decades, largely thanks to breakthrough medications called CFTR modulators. In late 2024, the U.S. Food and Drug Administration approved a powerful new triple-combination therapy called Alyftrek, building on the success of its predecessors and providing an important answer to the question: **What is the new drug for cystic fibrosis?**.

Cystic Fibrosis (CF) affects approximately 100,000 people worldwide [1.7.1, 1.7.2]. A key question in its management is, **which enzyme is used to treat cystic fibrosis?** The answer involves two main types of enzyme therapies targeting different symptoms: dornase alfa for the lungs and pancreatic enzymes for digestion.